Literature DB >> 31493541

Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients.

Li-Wen Huang1, Ying Sheng2, Charalambos Andreadis1, Aaron C Logan1, Gabriel N Mannis3, Catherine C Smith1, Karin M L Gaensler1, Thomas G Martin1, Lloyd E Damon1, Michael A Steinman4, Chiung-Yu Huang2, Rebecca L Olin5.   

Abstract

Allogeneic hematopoietic cell transplantation (alloHCT) has been increasingly offered to older adults with hematologic malignancies. However, optimal methods to determine fitness for alloHCT have yet to be defined. We evaluated the ability of a comprehensive geriatric assessment (CGA) to predict post-alloHCT outcomes in a single-center prospective cohort study of patients age 50 years and older. Outcomes included overall survival (OS), progression-free survival (PFS), and nonrelapse mortality (NRM). A total of 148 patients were included, with a median age of 62 years (range, 50 to 76 years). In multivariate regression analysis, several CGA measures of functional status were predictive of post-alloHCT outcomes, after adjusting for traditional prognostic factors. Any deficit in instrumental activities of daily living (IADL) was associated with inferior OS (hazard ratio [HR], 1.81, 95% confidence interval [CI], 1.07 to 3.08; P = .03) and PFS (HR, 1.85; 95% CI, 1.15 to 2.99; P = .01). A Medical Outcomes Study Physical Health scale (MOS-PH) score <85 was associated with inferior OS (HR, 1.96; 95% CI, 1.13 to 3.40; P = .02), PFS (HR, 1.75; 95% CI, 1.07 to 2.88; P = .03), and increased NRM (subdistribution HR, 2.57; 95% CI, 1.12 to 5.92; P = .03). MOS-PH score was also associated with the number of non-hematologic grade ≥3 adverse events within the first 100 days after alloHCT (rate ratio, 1.61; 95% CI, 1.04 to 2.49; P = .03). These findings support previous work suggesting that IADL is an important prognostic tool prior to alloHCT. MOS-PH is newly identified as an additional metric to identify older patients at higher risk of poor post-alloHCT outcomes, including toxicity and NRM.
Copyright © 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allogeneic transplantation; Functional status; Geriatric assessment

Mesh:

Year:  2019        PMID: 31493541      PMCID: PMC6942208          DOI: 10.1016/j.bbmt.2019.08.022

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  30 in total

1.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

2.  Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.

Authors:  Brian L McClune; Daniel J Weisdorf; Tanya L Pedersen; Gisela Tunes da Silva; Martin S Tallman; Jorge Sierra; John Dipersio; Armand Keating; Robert P Gale; Biju George; Vikas Gupta; Theresa Hahn; Luis Isola; Madan Jagasia; Hillard Lazarus; David Marks; Richard Maziarz; Edmund K Waller; Chris Bredeson; Sergio Giralt
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

3.  Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis.

Authors:  Barbara Deschler; Gabriele Ihorst; Susanne Schnitzler; Hartmut Bertz; Juergen Finke
Journal:  Bone Marrow Transplant       Date:  2018-01-12       Impact factor: 5.483

Review 4.  Geriatric syndromes and assessment in older cancer patients.

Authors:  A Naeim; D Reuben
Journal:  Oncology (Williston Park)       Date:  2001-12       Impact factor: 2.990

5.  Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT.

Authors:  Silke Heidenreich; Dimitris Ziagkos; Liesbeth C de Wreede; Anja van Biezen; Jürgen Finke; Uwe Platzbecker; Dietger Niederwieser; Hermann Einsele; Wolfgang Bethge; Michael Schleuning; Dietrich W Beelen; Johanna Tischer; Arnon Nagler; Bertram Glass; Johan Maertens; Lucrecia Yáñez; Yves Beguin; Heinz Sill; Christof Scheid; Matthias Stelljes; Arnold Ganser; Pierre Zachée; Dominik Selleslag; Theo de Witte; Marie Robin; Nicolaus Kröger
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-05       Impact factor: 5.742

6.  Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia.

Authors:  Ziyi Lim; Ronald Brand; Rodrigo Martino; Anja van Biezen; Jürgen Finke; Andrea Bacigalupo; Dietrich Beelen; Agnes Devergie; Emilio Alessandrino; Roel Willemze; Tapani Ruutu; Marc Boogaerts; Michele Falda; Jean-Pierre Jouet; Dietger Niederwieser; Nicolaus Kroger; Ghulam J Mufti; Theo M De Witte
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

7.  Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group.

Authors:  C L Loprinzi; J A Laurie; H S Wieand; J E Krook; P J Novotny; J W Kugler; J Bartel; M Law; M Bateman; N E Klatt
Journal:  J Clin Oncol       Date:  1994-03       Impact factor: 44.544

8.  The timed "Up & Go": a test of basic functional mobility for frail elderly persons.

Authors:  D Podsiadlo; S Richardson
Journal:  J Am Geriatr Soc       Date:  1991-02       Impact factor: 5.562

9.  Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies.

Authors:  Michael A Liu; Clark DuMontier; Anays Murillo; Tammy T Hshieh; Jonathan F Bean; Robert J Soiffer; Richard M Stone; Gregory A Abel; Jane A Driver
Journal:  Blood       Date:  2019-06-05       Impact factor: 25.476

10.  Evaluating cutpoints for the MHI-5 and MCS using the GHQ-12: a comparison of five different methods.

Authors:  Mark J Kelly; Frank D Dunstan; Keith Lloyd; David L Fone
Journal:  BMC Psychiatry       Date:  2008-02-19       Impact factor: 3.630

View more
  11 in total

1.  Allogeneic hematopoietic cell transplantation for older patients.

Authors:  Richard J Lin; Andrew S Artz
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults.

Authors:  Li-Wen Huang; Ying Sheng; Charalambos Andreadis; Aaron C Logan; Gabriel N Mannis; Catherine C Smith; Karin M L Gaensler; Thomas G Martin; Lloyd E Damon; Chiung-Yu Huang; Rebecca L Olin
Journal:  Transplant Cell Ther       Date:  2022-03-03

3.  Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan.

Authors:  Masamichi Isobe; Takaaki Konuma; Masayoshi Masuko; Naoyuki Uchida; Shigesaburo Miyakoshi; Yasuhiro Sugio; Shuro Yoshida; Masatsugu Tanaka; Yoshiko Matsuhashi; Norimichi Hattori; Makoto Onizuka; Nobuyuki Aotsuka; Yasushi Kouzai; Atsushi Wake; Takafumi Kimura; Tatsuo Ichinohe; Yoshiko Atsuta; Masamitsu Yanada
Journal:  Ann Hematol       Date:  2021-02-23       Impact factor: 3.673

4.  The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in older lymphoma patients.

Authors:  Richard J Lin; Laure Michaud; Stephanie M Lobaugh; Reiko Nakajima; Audrey Mauguen; Theresa A Elko; Josel D Ruiz; Molly A Maloy; Craig S Sauter; Parastoo B Dahi; Miguel-Angel Perales; Gunjan L Shah; Nerea Castillo Flores; Míriam Sanchez-Escamilla; Ana Alarcón Tomas; Lucrecia Yáñez San Segundo; Christina Cho; Ioannis Politikos; Soo Jung Kim; Beatriz Korc-Grodzicki; Sean M Devlin; Michael Scordo; Heiko Schöder; Sergio A Giralt; Paul A Hamlin
Journal:  Leuk Lymphoma       Date:  2020-03-31

5.  Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes.

Authors:  Rebecca L Olin; Caitrin Fretham; Marcelo C Pasquini; Mukta Arora; Vijaya R Bhatt; Benjamin Derman; Sergio A Giralt; Li-Wen Huang; Thuy Koll; Sang Mee Lee; Richard J Lin; Linda Pang; Uday R Popat; Daniel J Weisdorf; Andrew Artz
Journal:  Blood Adv       Date:  2020-06-23

6.  Discharge Disposition Following Hematopoietic Cell Transplantation: Predicting the Need for Rehabilitation and Association with Survival.

Authors:  Sarah A Wall; Qiuhong Zhao; Sumithira Vasu; Ashley Rosko
Journal:  Transplant Cell Ther       Date:  2020-12-17

Review 7.  Pitfalls and Successes in Trials in Older Transplant Patients with Hematologic Malignancies.

Authors:  Aaron T Zhao; Anthony D Sung
Journal:  Curr Oncol Rep       Date:  2022-01-21       Impact factor: 5.075

8.  Breaking the Age Barrier: Physicians' Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults.

Authors:  Asmita Mishra; Jaime M Preussler; Vijaya Raj Bhatt; Christopher Bredeson; Saurabh Chhabra; Anita D'Souza; Parastoo B Dahi; Eileen Danaher Hacker; Lohith Gowda; Shahrukh K Hashmi; Dianna S Howard; Ann Jakubowski; Reena Jayani; Thuy Koll; Richard J Lin; Rebecca L Olin; Uday R Popat; Cesar Rodriguez; Ashley Rosko; Mitchell Sabloff; Mohamed L Sorror; Anthony D Sung; Celalettin Ustun; William A Wood; Linda Burns; Andrew Artz
Journal:  Transplant Cell Ther       Date:  2021-04-06

Review 9.  Geriatric assessment in older patients with a hematologic malignancy: a systematic review.

Authors:  Ellen R M Scheepers; Ariel M Vondeling; Noortje Thielen; René van der Griend; Reinhard Stauder; Marije E Hamaker
Journal:  Haematologica       Date:  2020-05-07       Impact factor: 9.941

10.  Adaptation and Evaluation of a Symptom-Monitoring Digital Health Intervention for Patients With Relapsed and Refractory Multiple Myeloma: Pilot Mixed-Methods Implementation Study.

Authors:  Noa Biran; Robin Anthony Kouyaté; Emre Yucel; Gillian E McGovern; Antoinette M Schoenthaler; Olivia G Durling; Rashmi Unawane; Andrew Schutt; Sumeet Panjabi
Journal:  JMIR Form Res       Date:  2020-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.